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ABSTRACT
CONTEXT AND OBJECTIVES: Chronic myeloid leukemia (CML) requires strict daily compliance with oral 
medication and regular blood and bone marrow control tests. The objective was to evaluate CML pa-
tients’ perceptions about the disease, their access to information regarding the diagnosis, monitoring and 
treatment, adverse effects and associations of these variables with patients’ demographics, region 
and healthcare access.
DESIGN AND SETTING: Prospective cross-sectional study among CML patients registered with the Brazil-
ian Lymphoma and Leukemia Association (ABRALE).
METHODS: CML patients receiving treatment through the public healthcare system were interviewed 
by telephone. 
RESULTS: Among 1,102 patients interviewed, the symptoms most frequently leading them to seek medical 
care were weakness or fatigue. One third were diagnosed by means of routine tests. The time that elapsed 
between first symptoms and seeking medical care was 42.28 ± 154.21 days. Most patients had been tested 
at least once for Philadelphia chromosome, but 43.2% did not know the results. 64.8% had had polymerase 
chain reaction testing for the BCR/ABL gene every three months. 47% believed that CML could be controlled, 
but 33.1% believed that there was no treatment. About 24% reported occasionally stopping their medication. 
Imatinib was associated with nausea, cramps and muscle pain. Self-reported treatment adherence was signifi-
cantly associated with normalized blood count, and positively associated with imatinib. 
CONCLUSIONS: There is a lack of information or understanding about disease monitoring tools among 
Brazilian CML patients; they are diagnosed quickly and have good access to treatment. Correct compre-
hension of CML control tools is impaired in Brazilian patients.
RESUMO
CONTEXTO E OBJETIVOS: Leucemia mieloide crônica (CML) exige estrita adesão à medicação oral e ao 
monitoramento do sangue e da medula. O objetivo foi avaliar percepções de pacientes com leucemia 
mieloide crônica (LMC) sobre a doença, seu acesso à informação sobre diagnóstico, monitoramento e 
tratamento, efeitos adversos e a associação destes com dados demográficos, geográficos e de acesso 
a tratamento.
DESENHO E LOCAL: Estudo prospectivo transversal realizado com pacientes de LMC cadastrados na As-
sociação Brasileira de Leucemia e Linfoma (Abrale).
MÉTODOS: Pacientes com LMC recebendo tratamento do sistema público de saúde foram entrevistados 
por telefone.
RESULTADOS: Entre os 1.102 pacientes entrevistados, os sintomas mais frequentemente levando à busca 
de consulta foram fraqueza e fadiga. Um terço foi diagnosticado por exames de rotina. O tempo entre sin-
toma inicial e procura por ajuda foi de 42,28 ± 154,21 dias. A maioria foi testada pelo menos uma vez para o 
cromossomo Filadélfia, mas 43,2% não sabiam os resultados. 64,8% fizeram exame de reação em cadeia da 
polimerase para o gene BCR/ABL a cada três meses. 47% acreditavam que LMC pode ser controlada, mas 
33,1% acham que não há tratamento. Cerca de 24% disseram que ocasionalmente interrompem o trata-
mento. Imatinibe associou-se com náusea, câimbra e dor muscular. Aderência auto-reportada associou-se 
significativamente com hemograma normal e positivamente com uso de imatinibe.
CONCLUSÕES: Falta informação ou compreensão sobre monitoramento entre pacientes com LMC; eles 
recebem diagnóstico rapidamente e têm bom acesso ao tratamento. A correta compreensão das ferra-
mentas de controle em LMC está prejudicada entre eles.
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INTRODUCTION
Treatment of chronic myeloid leukemia (CML) used to include 
bone marrow transplantation, hydroxyurea and therapeutic reg-
imens based on interferon-alpha (IFN-alpha). About 10 years 
ago, imatinib mesylate, a derivative of phenyl-2-amino-pyrim-
idine that is a selective inhibitor of BCR-ABL tyrosine kinase, 
which induces hematological and cytogenetic remission in CML 
cases, became the treatment of choice.1 The average age of 50 
years among patients originally affected by CML (median of 60), 
as well as the lack of histocompatible donors and the early and 
late risks, limits the option of bone marrow transplantation to a 
minority of patients.2-4 Imatinib mesylate is a drug with proven 
efficacy for treating patients with CML and is indicated as first-
line medication for patients with Philadelphia chromosome 
(Ph+) positive CML (a chromosomal translocation associated 
with CML that is used in diagnosing the disease).5,6 Today, second-
generation tyrosine kinase inhibitors such as dasatinib and nilo-
tinib have also been shown to be efficacious as first-line therapy.7-10 
Every Brazilian citizen has the right to receive imatinib mesylate 
for treatment of CML, on a cost-free basis, provided by the gov-
ernment. However, no study has investigated the access to these 
treatments in Brazil yet. 
This chronic disease may cause significant changes to the 
daily lives of individuals and their families,11,12 since manage-
ment of this disease involves strict daily compliance with oral 
medication and regular blood and bone marrow control exami-
nations.13,14 In the context of chronic diseases, cancer is seen in 
the popular imagination as a cause of rapid finitude and suffer-
ing, among other meanings. Although there are cultural differ-
ences in how the disease and patients’ expectations regarding 
the physician’s role are viewed,15 even without universal poli-
cies to inform and involve patients in decisions that affect their 
care,16 most patients want information about their diagnosis and 
want their families to also be informed, even when their illnesses 
are severe.17-20 This has proved to be an important therapeutic 
tool,13,21 and some authors have suggested that this information 
decreases the patient’s sense of isolation and contributes towards 
mutual cooperation in the doctor-patient relationship.21 
Hematology-oncology is a specialty that deals with patients 
who now can count on increased survival based on the proposed 
treatments – treatments that, of course, are not without risks or 
side effects, but are tolerable. However, few studies have been con-
ducted in Brazil to determine patients’ desire to participate in 
treatment decisions, and there have not been any studies specifi-
cally on CML patients that have assessed their access to treatment 
and the time required for a diagnosis to be reached. Since there 
may be significant differences in patients’ perceptions of the qual-
ity and quantity of information received and in their participation 
in medical decisions among populations in different countries, it 
is important that studies like this should be conducted in Brazil.17 
OBJECTIVE
The purpose of this study was to evaluate Brazilian CML patients’ 
perceptions about the disease, their access to information regard-
ing the diagnosis, treatment and care received, adverse effects and 
relationships with doctors; and associations of these variables 
with patients’ demographics, region and access to healthcare.
METHODS
Design, participants and location
This was a prospective, longitudinal study among patients with CML 
who were registered with the Brazilian Lymphoma and Leukemia 
Association (ABRALE). ABRALE is a civil society organization 
formed by patients with leukemia and lymphoma and their families, 
which provides information and support to patients, and educa-
tional programs, publications and events to healthcare professionals 
across the country. The study was approved by the Ethics Committee 
of the Albert Einstein Institute for Teaching and Research.
During the period between April 28, 2008, and February 8, 
2010, all patients registered with ABRALE were surveyed by tele-
phone about the care they had received for this disease. Patients 
were enrolled if they had a diagnosis of CML and were registered 
in ABRALE. Patients are registered with ABRALE through direct 
enrolment in the healthcare services where they are treated, in 
eight Brazilian state capitals (Rio de Janeiro, Curitiba, Goiânia, 
Recife, Porto Alegre, Belo Horizonte, São Paulo and Salvador) 
and in the city of Campinas (state of São Paulo). All the partici-
pants were interviewed 1 to 3 times, and were asked about their 
perceptions of the disease and its treatment, the drugs they were 
using and any adverse effects, and their relationships with their 
doctors. A questionnaire was specially designed for this study, 
including questions concerning the variables below. 
Patients registered with ABRALE, i.e. patients undergo-
ing treatment for CML who were receiving drugs through the 
Brazilian public healthcare system (SUS, Sistema Único de Saúde), 
were included. The telephone number in ABRALE’S records was 
used to contact patients as many times as needed until they had 
time to be interviewed. Deceased patients and those whose con-
tact information in the database was out of date or incorrect were 
excluded. If patients could not or did not want to participate in an 
interview at the first contact (because they were busy or not feel-
ing well), they were called at least one more time. Sometimes, they 
were called more than three times. If in the end they could not be 
reached, they were excluded from the study. 
Variables studied
The patients’ demographic characteristics, such as age, educa-
tion level, geographic location and access to healthcare services 
were checked. The symptoms that led patients to seek healthcare, 
their specialists, the tests that were requested and performed 
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(i.e. how the disease was diagnosed), and the time that elapsed 
between symptoms and the diagnosis, were recorded. The treat-
ments and procedures performed (medications taken and bone 
marrow transplantation performed) and adverse effects and 
access to healthcare services and medication were also recorded. 
In addition, the patients’ knowledge and awareness of their dis-
ease and its prognosis and their relationships with their families 
and friends were analyzed.
Interviews
Three nurses who had previously been trained for this task, with 
clarifications about CML and the treatments available, conducted 
the telephone interviews. In order to reach the interviewees at a 
time when the interview would be possible, they made at least 
three calls to the home or mobile phone numbers of the patients 
registered at ABRALE (i.e. if the interview could not take place 
at the first contact, a second and/or a third attempt was made).
The interviews were conducted by telephone using three 
questionnaires specially formulated for this study. During the first 
contact, which was made between April and July 2008,  the 
patients’ demographic variables and the first data about symp-
toms, diagnosis and treatment were assessed. During the sec-
ond contact, between August 2008 and January 2009, the same 
patient reported whether his or her treatment had been modified 
and whether there had been any adverse effects or any difficulties. 
During the third contact, which occurred between March 2009 
and July 2010, the patient was asked about his or her treatment, 
any tests performed and their psychological care. The interviews 
lasted about 15 to 20 minutes. The responses were entered into 
computerized databases.
Statistical analysis
The characteristics of the patients and their disease were described 
using absolute and relative frequencies of the categories of inter-
est. The chi-square or likelihood ratio test was applied to deter-
mine whether there was any association between the categorized 
measurements of interest. The Kruskal-Wallis test was performed 
to compare demographics with questions related to treatment 
adherence. For statistical analysis, the Statistical Package for the 
Social Sciences (SPSS), version 15.0, was used.
RESULTS
Patients and care
During the study period, 1,102 patients with CML were interviewed. 
The patients’ average age at the time of the interview was 47.8 years. 
The average age at diagnosis was 42 years (range: 3 to 84 years).
Most patients (75.86%) were from the southern and south-
eastern regions of Brazil. Although all of them were entitled to 
free care through SUS in Brazil, and were even receiving the 
cancer treatment drugs through the Brazilian public health-
care system, 44.8% of the respondents also had a private health 
plan or insurance. Most of these were in the southeastern region 
(P < 0.001), whereas the remainder depended solely on public 
assistance.
Just over half (51.4%) of the respondents had had to travel to 
another city to get specialized care. Most of the Brazilians who 
had had to travel to receive treatment were living in the northern 
region (73.3% had to travel) and southern region (63.3% had to 
travel). The region of residence was significantly associated with 
the need to travel (P < 0.001).
Diagnosis and follow-up
The first symptoms that most frequently led the respondents to 
seek medical help were weakness or fatigue (45.5%), weight loss 
(36.3%) and bone pain (22.4%). Only 9.1% had fever. One third 
(33.8%) of the patients discovered that they were sick from tests 
that were usually performed due to other clinical suspicions, and 
4.5% had anemia.
The time that elapsed from experiencing the first symptoms 
to seeking initial medical help varied widely, with an average of 
42.28 ± 154.21 days. There was no association between this inter-
val and the patient’s region of residence. The time that elapsed 
between the first visit to a general practitioner and a consultation 
with a specialist was also checked. The median time was three 
days, but the variation was wide. Again, there was no association 
between the elapsed time and the geographical region.
The patients were asked whether they had been tested for the 
presence of the Philadelphia chromosome after beginning treat-
ment for CML, and the responses are shown in Table 1. Most of 
the patients had been tested at least once. Twenty percent of the 
patients did not answer the question regarding the frequency with 
which they were tested. Among those who responded, most stated 
that they had been tested for the Philadelphia chromosome once 
(33.3%) or twice (34%) yearly. A small proportion (5.8%) said they 
had been tested 4 times yearly. The remaining patients stated that 
they had been tested once every two years (5.4%), did not know the 
frequency of testing (13.3%), or that “they were no longer tested” 
(8.2%), meaning that they had probably only been tested once.
Among the interviewees, 43.2% could not say whether the 
Philadelphia chromosome test became negative after they had 
Table 1. Patients’ responses to questions about the date of the 
Philadelphia chromosome test
93.3% had been tested
33.6% did not recall the date
21.8% up to six months ago
35.1% six months to one year ago
2.8% over one year ago
5.1% had not been tested
2.3% indicated the reason as “recent diagnosis”
2.8% indicated no reason at all
1.6% had never heard of the test
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taken the medication, 36.1% reported that the test became nega-
tive and 20.8% that it was non-negative. There was no association 
between knowledge of the test result and the participant’s geo-
graphical region.
The patients were also asked whether they had had the poly-
merase chain reaction (PCR) test to count the number of copies 
of the BCR/ABL gene; 64.8% of respondents revealed that they 
had had the test every three or six months, or every year. A few 
said they had never had the test (1.2%) or that they had had the 
test “every month” (6.6%), and 26.3% stated that they did not 
know about the PCR test. Again, there was no significant associa-
tion between knowledge or frequency of the test and the partici-
pant’s geographical region.
In order to investigate the frequency of monitoring with a 
complete blood count (CBC), the participants were asked when 
they had last had this test. The vast majority (92.9%) had under-
gone blood counts one, two or three months previously. Others 
(7.1%) reported that more than three months had elapsed since 
having the test. The vast majority reported that “the blood test 
was normal” as a result of taking the drug (80.7%), but 13.8% 
said that their test was not normal and 5.4% said that they did 
not know the test result.
Perceptions of the disease and its treatment
Most participants knew something about the disease before 
receiving their diagnosis of leukemia (67.5%) or had cases in the 
family (6.2%). However, 26.3% had never heard of the disease.
The survey also addressed the relationship between patients 
and their doctors. Most patients said that they “always” (76.1%) 
or “sometimes” (15.6%) asked the doctor questions to clarify 
their doubts. Only a small portion (2.5%) stated that the consul-
tation time was too short to ask questions or that they had diffi-
culty understanding the doctor (2%). Those who answered that 
they did not have a good relationship with their doctor sought 
other means of informing themselves (3.8%).
Most of the patients relied on the treatment. Most believed 
that “there is a treatment for CML and, if followed, the disease 
will be controlled” (47%), or even that after some time on treat-
ment “the person is cured” (19.9%). But 33.1% were skeptical; 
they believed that there was no treatment to even control the dis-
ease. There was no association between these responses and the 
frequency with which the drugs were taken.
The diagnosis of leukemia improved half (50.7%) of the 
patients’ relationships with family and friends, whereas it 
remained the same for 42%. Only 7.3% said that the relation-
ship with other people had worsened. There was an associa-
tion between little emotional support received by patients from 
their family and a feeling among patients that that the diagno-
sis had worsened their relationship with their family and friends 
(P  =  0.001). Situations in which patients were close to their 
partners were also associated with receiving support from their 
family (r = 0.522, P = 0.0001) and with being satisfied with 
their sex life (r = 0.544, P = 0.0001).
Being concerned about possible worsening was a response 
correlated with the fear of having new disease symptoms 
(r  =  0.582, P = 0.0001). On the other hand, patients who said 
they were able to work felt fulfilled with the work they performed 
(r =  0.611, P = 0.0001) and were also able to perform their usual 
activities (r = 0.601, P = 0.0001).
Diet did not change for 61.5% (although 52.7% reported 
experiencing changes in appetite); 71.2% did not cease to do 
physical activities, and 57.7% did not interrupt their work.
Undergoing bone marrow transplantation was positively 
associated with the response to the question of how the patients 
faced the disease (P = 0.002) and how much pleasure in life they 
felt (P = 0.004), thus revealing an association between these three 
aspects of the patients. Transplantation also was significantly 
associated with a change in eating habits (P < 0.01) and having a 
good appetite (P = 0.030).
Most patients (74.4%) believed that their health had improved 
with the various treatments that had been applied; 6.9% thought 
it had worsened, and 18.7% saw no difference. A portion of them 
(23.3%) reported that their health had worsened at some point 
during their therapy.
Among the 1,097 respondents, 78.3% believed that their 
attitude could influence the result of their treatment, and 3.2% 
thought that only some attitudes interfered. On the other hand, 
18.3% of the patients believed that no action of theirs could inter-
fere with their treatment. The response to the question regard-
ing the interference of certain actions with success of treatment 
was not significantly associated with reports of disruption in 
taking medication. During the first interview, only 6.5% of the 
patients admitted that they had discontinued their medication at 
some time on their own. However, 24.4% revealed that they had 
stopped taking their medication on some days (failure to take the 
medication or running out of the drug), and 24.0% stated that 
this had occurred during the past month.
As already stated, every Brazilian citizen has the right to 
receive medication for treatment of CML, on a cost-free basis, 
and this is provided by the government. As shown in Table 2, 
Table 2. Average proportions of treatments reported as used 
during the three interviews (n = 1102)
Treatment
Research
n (%)
Imatinib 801.67 (72.73%)
Bone marrow transplantation 82.67 (7.50%)
Tyrosine kinase inhibitors, second generation 84.67 (7.67%)
Interferon 14.67 (1.33%)
None 26.0 (2.35%)
Others 94.50 (8.50%)
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most patients were on imatinib during the three stages of the 
study. The use of the different treatments did not change much 
over time; 52.2% of the patients said that they were currently 
taking drugs that had been prescribed for them for two or more 
years, and 15% for at least one year.
Most patients (75.95%) said that they had not experienced dif-
ficulties in receiving their medication from the government for 
treatment of CML. The least difficulty was reported in the south-
ern and southeastern regions (P < 0.01; likelihood ratio test). Most 
(79.2%) also had not had any difficulty receiving the drugs during 
the month preceding the survey (again, with a predominance of 
easy access in the southern and southeast regions; P < 0.001).
Among 243 patients who said that they had failed to take 
the drug at some time in the past month, 90 (8.2% of the total 
sample) said that this was due to forgetfulness, 38  (3.4%) 
due to medical advice, and 81 (7.4%) because of a lack of 
the medicine, with no information available about the rea-
son for the remaining 34 patients. On average, these patients 
went 10 days without taking the drug (median: 3 days); 22% 
said that they had not paid proper attention to the schedule 
for taking the medicine, and 3% admitted to having reduced 
or increased the doses on their own.
In most cases, imatinib was associated with the following side 
effects: nausea (54.6%, P < 0.001), cramps (65.4%, P < 0.001) and 
muscle pain (52.3%, P < 0.001).
As shown in Table 3, there was a significant association 
between continuity in taking the prescribed medication (self-
reported) and normalization of blood counts. This correlation 
was positive with the drug imatinib (i.e. between use of the drug 
and normalization of the test).
DISCUSSION
This was the largest study on patients’ perceptions of CML diag-
nosis and treatment in Brazil, interviewing 1,102 patients.
The goal in this study was to evaluate how treatment is dis-
tributed in the country and the difficulties faced by patients with 
regard to access to treatment and information about the disease. 
We found that the majority of the patients lived in the southeast-
ern region of Brazil, where the treatment of CML is still heavily 
concentrated. Although public healthcare in Brazil is distributed 
throughout the country, treatments of high complexity still tend 
to be concentrated in the southeastern region. Particularly for 
CML, the expanded access program for imatinib began in cen-
ters located in this region, and many patients maintained their 
treatment there, despite widespread free distribution of the drug 
by the federal government in all states.22 
This study found that fatigue or weakness was the symptom 
most frequently leading patients with CML to seek medical help 
and have the disease diagnosed. In another study showing the 
characteristics of CML patients during their first visit to health-
care services, 40% were asymptomatic; however, among the 
symptomatic patients, fatigue, anorexia and weight loss were typ-
ical symptoms. For 40% of those asymptomatic patients, the diag-
nosis was made from abnormal granulocytic counts seen in the 
blood analysis, which were present in up to half of the patients.23 
Perhaps the use of a symptom as nonspecific as fatigue explains 
why there are huge variations in the time that elapses from expe-
riencing the first symptoms to seeking medical help, as seen in 
the present study. While some patients sought help within the 
first days after the appearance of symptoms, others took months 
to do so, and it was not possible to establish a pattern of behav-
ior in this study. The onset of symptoms in a chronic disease like 
CML occurs at varying times, which may explain this finding.
A major problem today in using tyrosine-kinase inhibitors is 
adherence: these drugs are able to adequately control the disease, 
but with the need for medicine to be taken daily. A recent study 
on the impact of adherence to imatinib on survival found that, at 
some point during treatment, 29.6% of the patients were consid-
ered to be nonadherent (using the criterion of discontinuation 
of treatment, without any medical prescription for more than 
one week). These nonadherent patients were more likely to fail 
to achieve a complete cytogenetic response and had shorter sur-
vival.24 Among patients with CML treated with imatinib for some 
years, poor adherence may be the predominant reason for inabil-
ity to obtain adequate molecular responses,25-27 i.e. a reduction in 
BCR-ABL1 transcripts, or a cytogenetic response.25,26 Treatment 
adherence to imatinib should be monitored routinely28,29 because 
noncompliance leads to poor response to treatment and higher 
costs.25,28,30-32 Treatment interruptions (i.e. failure to refill the ima-
tinib prescription) can be detected by many adherence measure-
ment tools in current use for imatinib: the medication possession 
ratio (MPR),27,28,32 retrieval of medication from the healthcare 
services providing them,25,33 or simply by monitoring plasma 
levels.31,34 Therefore, blood samples should be taken regularly in 
order to evaluate disease control and medicine intake.
One important finding of this study was the poor under-
standing that the patients had about the diagnostic and moni-
toring tools for the disease. Information is only one of the many 
challenges facing leukemia patients and their caregivers, as 
recently shown.12 For example, although most patients in our 
study remembered being tested for the Philadelphia chromo-
some, only 20% knew the frequency of testing, 33.6% did not 
know the date of the last test and many did not know what the 
result of the test was. This finding is interesting because the test 
for the Philadelphia chromosome involves collecting bone mar-
row (for a myelogram), which usually does not go unnoticed. 
Although bone puncture is always done under anesthesia, it is 
an unusual and uncomfortable examination that is difficult to 
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forget. Karyotyping is necessary in order to monitor the status of 
the Philadelphia chromosome and, in patients with CML, should 
be performed periodically.
In a study on physicians affiliated to the Latin America 
Leukemia Net (LALNET), 72% stated that they did bone marrow 
karyotyping to monitor their patients, 54% said that they per-
formed the test every six months, and 31% said that they per-
formed the test every four months.35 In Brazil, as seen in this 
study, patients reported a curious lack of information or diffi-
culty in understanding the schedule for the monitoring of their 
disease. We found that the same “misinformation” occurred with 
the PCR test; 26.3% of the patients in this study were not famil-
iar with the test. The LALNET study showed that 41% of Latin 
American doctors prescribed the PCR test every six months 
and 31% every three months.35 Considering that the physicians 
reported complying with the international monitoring recom-
mendations, the finding in this study may reflect a lack of under-
standing among patients regarding the monitoring schedule (for 
example, confusion between CRP and CBC, which are both eval-
uated by collecting venous blood) and regarding the usefulness of 
each test, despite the efforts of the healthcare providers and asso-
ciations such as ABRALE to educate this population about their 
illness and its treatment. A multidisciplinary approach may be a 
good tool for dealing with this challenge.13 
While demonstrating less knowledge than they should about 
their own health monitoring, the patients interviewed seemed 
Table 3. Association between normal results in the complete blood count (CBC) and treatments in patients with chronic myeloid leukemia
Was your CBC (hemogram) test normal?
Yes No Don’t know Total P
n % n % n % n %
At the last interview you said you 
were taking [........]. Are you still 
taking it?
Yes 809 91.1 126 82.9 48 80.0 983 89.4
0.001No 79 8.9 26 17.1 12 20.0 117 10.6
Total 888 100.0 152 100.0 60 100.0 1100 100.0
Bone marrow transplantation
No 821 92.4 144 94.7 52 86.7 1017 92.4
0.161*Yes 68 7.6 8 5.3 8 13.3 84 7.6
Total 889 100.0 152 100.0 60 100.0 1101 100.0
Aracytin (chemotherapy)
No 888 99.9 151 99.3 60 100.0 1099 99.8
0.445*Yes 1 0.1 1 0.7 0 2 0.2
Total 889 100.0 152 100.0 60 100.0 1101 100.0
Dasatinib
No 831 93.5 136 89.5 56 93.3 1023 92.9
0.240*Yes 58 6.5 16 10.5 4 6.7 78 7.1
Total 889 100.0 152 100.0 60 100.0 1101 100.0
Interferon
No 883 99.3 146 96.1 60 100.0 1089 98.9
0.007*Yes 6 0.7 6 3.9 0 12 1.1
Total 889 100.0 152 100.0 60 100.0 1101 100.0
Imatinib
No 225 25.3 63 41.4 27 45.0 315 28.6
< 0.001Yes 664 74.7 89 58.6 33 55.0 786 71.4
Total 889 100.0 152 100.0 60 100.0 1101 100.0
Hydroxyurea
No 866 97.4 132 86.8 54 90.0 1052 95.5
< 0.001*Yes 23 2.6 20 13.2 6 10.0 49 4.5
Total 889 100.0 152 100.0 60 100.0 1101 100.0
Nilotinib
No 850 95.6 143 94.1 56 93.3 1049 95.3
0.569*Yes 39 4.4 9 5.9 4 6.7 52 4.7
Total 889 100.0 152 100.0 60 100.0 1101 100.0
None
No 866 97.4 147 96.7 56 93.3 1069 97.1
0.269*Yes 23 2.6 5 3.3 4 6.7 32 2.9
Total 889 100.0 152 100.0 60 100.0 1101 100.0
Other
No 874 98.3 150 98.7 58 96.7 1082 98.3
0.640*Yes 15 1.7 2 1.3 2 3.3 19 1.7
Total 889 100 152 100 60 100 1101 100
Results from the association tests, chi-square test or *likelihood ratio test.
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satisfied with the doctor-patient relationship. Only 2% said that 
the consultation time was too short. These responses are contra-
dictory, since they indicate an impossible scenario; patients say 
they are satisfied with their relationship with their doctor and 
that the consultation time is satisfactory, but they do not know 
when the last karyotyping for detection of the Philadelphia chro-
mosome occurred.
One possible explanation could be that the language used 
by the doctor might not be effective in communicating with the 
patient. Another could be that the patients themselves have little 
interest in finding out about their own disease. The emotional 
aspects of CML patients were also addressed by the survey, and 
33.1% were skeptical and believed that there was no treatment 
to even control their disease. Possibly, some of these patients do 
not seek information from their doctor or other sources, owing 
to their disinterest and lack of hope. Nonetheless, these specula-
tions must be investigated more appropriately.
Another study on adherence to chemotherapy mapped 
the steps involved in complex processes like adherence, includ-
ing the prescription, drug delivery, administration and phases 
of drug use, also including reports of adverse effects made by 
patients. “Make lists to guide and remind clinicians about the 
key  elements of patient education” was the authors’ main rec-
ommendation with regard to imatinib, and to “offer patients 
and their families educational materials about the protocols, and 
a phone number to resolve questions”.36 In fact, there is already a 
consensus that proper education of patients can reduce the risk 
of noncompliance,28,30,32 and consequently reduce the economic 
burden of CML. Additionally, the patient is the main guardian of 
his/her treatment and disease monitoring: the results from treat-
ing CML depend not only on taking the medicine appropriately 
but also on clinical decisions based on hematological, cytogenetic 
and molecular controls. 
The factors known to predict adherence to therapy include 
information about the disease,37-39 frequent contact with a sin-
gle hematologist, easy access to the treatment clinic38,39 and par-
ticipation in decision-making about the disease and treatment.38 
A study has shown that patients felt inappropriately reassured by 
physicians that their nonadherence would not have a detrimental 
effect on their clinical response.40 Therefore, information about 
the patients’ perceptions and their level of knowledge on the sub-
ject is very useful for clinicians and will certainly help in manag-
ing the disease, quality of life and treatment outcomes.
Our study was conducted in three stages. Although we did not 
evaluate adherence directly, we had the opportunity to ask patients 
about their use of medication. The proportions of patients using dif-
ferent CML treatments had not changed significantly over time, with 
most using imatinib. Few patients in this study reported forgetful-
ness or admitted that they intentionally stopped taking the medicine. 
In Brazil, CML is diagnosed quickly. Patients have good 
access to treatment and understand that although the disease is 
not curable, it can be controlled with medication. Many believed 
that the occurrence of the disease helped improve their relation-
ships with family and friends. However, there are still small pro-
portions of patients who remain skeptical about the effectiveness 
of the treatment.
From the results of this study, we recommend that patients be 
given information about the importance and significance of peri-
odic tests to monitor CML, since many are still ignorant of essen-
tial tests like that for the Philadelphia chromosome.
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